title: Vitamin D metabolism in myeloma.
abstract: We measured serum concentrations of vitamin D metabolites in 27 patients with myeloma, 16 of whom were hypercalcaemic. Serum values were compared with values from normal controls. Serum concentrations of calcitriol (1.25-dihydroxyvitamin D; 1.25(OH)2D3) were decreased in both hyper- and normocalcaemic patients, but more markedly so in hypercalcaemia. These findings were not solely due to impaired renal function nor due to an inadequate supply of 25-hydroxyvitamin D, and in hypercalcaemic patients were reversed by diphosphonate treatment. We conclude that hypercalcaemia in myeloma is not mediated by abnormalities in vitamin D metabolism. Decreased serum concentrations of 1.25(OH)2D3 may adversely affect both skeletal and tumour metabolism.
authors: Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School.
authors: P
authors: P
authors: Lawson-Matthew
authors: J
authors: J
authors: Clayton
authors: D
authors: D
authors: Guilland-Cumming
authors: A
authors: A
authors: Yates
authors: E
authors: E
authors: Preston
authors: M
authors: M
authors: Greaves
authors: J A
authors: JA
authors: Kanis
mesh_terms: D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000378:metabolism*; D014807:Vitamin D / Q000378:metabolism*
chemical_list: D014807:Vitamin D; D002117:Calcitriol